Next Generation Therapeutics
Focused on Non-Surgical Tissue Repair

Validated enzymatic technology platform: NexoBrid®, a commercial drug for severe burns; EscharEx®, a late-stage therapy for wound care; MW005 a clinical-stage biotherapy for non-melanoma skin cancers

Global Strategic Partnerships with Vericel, Kaken, 3M, Mölnlycke, MIMEDX, BARDA, DoD, PMI, BSV

Solid Balance Sheet

EscharEx®: The Game Changer
Next generation enzymatic therapy for wound care
Significant unmet medical need for topical, rapid and effective debridement agent in outpatient settings
In controlled Phase II studies:
- EscharEx demonstrated a significantly higher incidence of complete debridement. (9 days vs. 59 days for patients treated with SOC)
- Complete debridement was achieved with an average of 3.6 topical applications of EscharEx, whereas the SOC required an average of 12.8 applications.
Demonstrated safe, effective and rapid debridement in VLUs and DFUs; reduced wound size, reduction in biofilm and bacterial burden
Targets a 2B$ market opportunity - anticipated to draw market share from all other debridement modalities
Patient enrollment H2 2024

NexoBrid®: Profitable & Validated
Disruptive therapy for burn care; FDA and EMA approved
Clear unmet need for early, effective and selective non-surgical eschar removal for severe burns
Clinically and commercially validated
Strategic alliances: Vericel, Kaken, 3M, Mölnlycke, MIMEDX, BARDA, DoD, PMI, BSV
Approved in 44 countries; more than 12K patients treated successfully worldwide
Approved in Europe and Japan for all ages

MW005: Novel Biotherapy
Biotherapy for non-melanoma skin cancers
US Phase I/II study, demonstrated efficacy, safety and tolerability
Easy to use, high potency, 5-7 topical applications
4.3M annual cases of basal cell carcinoma (BCC) diagnosed in the US, need to replace surgery as the current standard of care (SOC).

Solid balance sheet to support EscharEx® clinical development program
Cash of $46M
2022 revenues of 26.5M, NexoBrid is profitable
2023 product revenues >30% growth
This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. These forward-looking statements are based on management’s expectations as of the date hereof and assumptions which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. The use of words such as “intend” and “expect,” among others, generally identify forward-looking statements. However, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates. Actual results and the timing and outcome of events may differ materially from those expressed or implied in the forward-looking statements for a variety of reasons, including those detailed in MediWound’s annual report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022, Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. Except as required by law, we undertake no obligation to update any forward-looking or other statements in this release, whether as a result of new information, future events or otherwise.

Certain data in this page, was obtained from various external sources, and neither the Company nor its affiliates, advisors or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisors or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation.